Metis TechBio Co Ltd/ADR
No enriched coverage for $MTBOY in the last 7 days.
No SEC Form 4 filings for $MTBOY in the last 30 days.
See all $MTBOY insider activity →Metis TechBio, a Hong Kong-listed biotech, has partnered with Eli Lilly for up to $1.1 billion to develop AI-driven drug-delivery technologies. Metis will receive an upfront payment and potential milestone payments, plus royalties on sales. The collaboration aims to improve tissue targeting for LNP-based therapies.
Metis TechBio, a Hong Kong-listed biotech, has partnered with Eli Lilly for up to $1.1 billion to develop AI-driven drug-delivery technologies. Metis will receive an upfront payment and potential milestone payments, plus royalties on sales. The collaboration aims to improve tissue targeting for LNP-based therapies.
AlphAI scores every news story that mentions MTBOY with an AI model for sentiment and relevance, and aggregates insider trades from Metis TechBio Co Ltd/ADR's SEC EDGAR Form 4 filings. Figures refresh continuously.
Metis TechBio, a Hong Kong-listed biotech, has partnered with Eli Lilly for up to $1.1 billion to develop AI-driven drug-delivery technologies. Metis will receive an upfront payment and potential milestone payments, plus royalties on sales. The collaboration aims to improve tissue targeting for LNP-based therapies.
2 min read
